KORU Medical Systems, Inc. — Form 8-K
Filed August 5, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 42/100
What the filing says
KORU Medical reported Q2 2026 net revenues of $12.0M (18% YoY growth), gross profit of $7.8M (65.1% margin), and net income of $0.25M versus a $0.2M loss in Q2 2025. The company acquired a connected monitoring technology asset (intangible asset investment of $961K, partly settled via 125,628 share issuance worth $500K). KORU withdrew its 510(k) application for FreedomEDGE with Phesgo in the U.S. oncology market and shifted strategy to higher-volume molecules. Full-year 2026 guidance was narrowed to $47.5–$48.5M revenue (15–18% growth), 62–64% gross margin, positive adjusted EBITDA, and year-end cash >$7.5M.
Why this rating
Solid operational progress (18% growth, profitability inflection) is good, but represents normal business execution at ~$119M market cap. Strategic shift away from Phesgo is a modest pivot, not transformational. Technology acquisition ($500K equity issued) is small relative to company size. Guidance narrowing shows confidence but no material trajectory change.
See more from August 5, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.